- Coordinator
- European Research Infrastructure on Highly Pathogenic Agents, Belgium
- Runs
- 1 January 2024 to 31 December 2026
- Status
- Running
- EU funding
- €1.5m
- Total cost
- —
- Partners
- 24 organisations in 20 countries
- Type
- Coordination and Support Action
- Grant agreement
- 101132215
What the project is doing
In the project's own words, from its summary on CORDIS.
Emerging infectious diseases (EID) do not respect borders. They rank as global catastrophic risks for humanity, along with climate change and biodiversity loss. The COVID-19 pandemic showed how coordination of global research, through cooperation, and sharing of data and expertise, are crucial for efficient and effective preparedness to EIDs, and vital for a rapid response. Nevertheless, there are still major challenges limiting global cooperation among high containment laboratories (HCLs).
HCLs are critical infrastructures for the development of medical countermeasures (e.g., vaccines and therapeutics) against high consequence pathogens. In order to fulfil its role, and given the global threat of EIDs, the European Research Infrastructure on Highly pathogenic Agents (ERINHA), together with its partners, proposes to establish and reinforce interactions with HCL research infrastructures (RI) worldwide, to strengthen pandemic preparedness and response capacities.
INTERCEPTOR (INTERnational Cooperation of high containment research infrastructures: from Epidemic Preparedness TO Response), a consortium with key HCLs from Europe and across the world, will focus on access provision to HCLs, enhancement of the human capital of HCL, including in biorisk management, critical resources sharing, harmonisation and interoperability. The proposed actions will help ensure broader access to state-of-the-art HC facilities, while respecting the necessary biosecurity and biosafety constraints, and promote the establishment of a sustainable global network of HC RIs.
By expanding access to HC RIs, strengthening the human capital base, promoting sharing of knowledge, skills and experience, and providing opportunities for common training programmes and staff exchanges, INTERCEPTOR will reinforce the next generation of HCL researchers and facility managers, and extend the opportunities for access to HCLs, required to push the boundaries of science and innovation in the field of EIDs.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| European Research Infrastructure on Highly Pathogenic Agents | Bruxelles / Brussel | Belgium | Coordinator |
| Medizinische Universitat Graz | Graz | Austria | Participant |
| Commonwealth Scientific and Industrial Research Organisation | Acton Act | Australia | Participant |
| Centro Nacional De Pesquisa Em Energia E Materias Associacao Privada | Campinas | Brazil | Associatedpartner |
| Fundacao Oswaldo Cruz | Rio De Janeiro | Brazil | Associatedpartner |
| University of Saskatchewan | Saskatoon | Canada | Associatedpartner |
| Eidgenossisches Departement Fur Verteidigung, Bevolkerungsschutz Und Sport | Bern | Switzerland | Participant |
| Philipps Universitaet Marburg | Marburg | Germany | Participant |
| Robert Koch-Institut | Berlin | Germany | Associatedpartner |
| Instituto De Salud Carlos Iii | Madrid | Spain | Participant |
| Institut National De La Sante Et De La Recherche Medicale | Paris | France | Participant |
| Nemzeti Nepegeszsegugyi Es Gyogyszereszeti Kozpont | Budapest | Hungary | Participant |
| Pecsi Tudomanyegyetem - University of Pecs | Pecs | Hungary | Associatedpartner |
| Istituto Nazionale per Le Malattie Infettive Lazzaro Spallanzani-Istituto Di Ricovero E Cura a Carattere Scientifico | Roma | Italy | Participant |
| Institut Pasteur Korea | Seongnam-Si | South Korea | Associatedpartner |
| University of Malaya | Kuala Lumpur | MY | Associatedpartner |
| Erasmus Universitair Medisch Centrum Rotterdam | Rotterdam | Netherlands | Associatedpartner |
| Instituto Nacional De Saude Dr. Ricardo Jorge | Lisboa | Portugal | Participant |
| Folkhalsomyndigheten | Solna | Sweden | Participant |
| A*STAR Infectious Diseases Labs | Singapore | SG | Associatedpartner |
| National University of Singapore Public Company Limited by Guarantee | Singapore | SG | Associatedpartner |
| Department of Health | Leeds | United Kingdom | Participant |
| The University of Texas Medical Branch at Galveston | Galveston | United States | Associatedpartner |
| National Health Laboratory Services | Sandringham | South Africa | Participant |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI